
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6860388/publications.pdf Version: 2024-02-01



ANDREAL COX

#	Article	IF	CITATIONS
1	Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science, 1992, 255, 1261-1263.	6.0	1,189
2	ldentification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science, 1994, 264, 716-719.	6.0	812
3	Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science, 1992, 256, 1817-1820.	6.0	672
4	Protection against persistence of hepatitis C. Lancet, The, 2002, 359, 1478-1483.	6.3	426
5	The effects of female sex, viral genotype, and <i>IL28B</i> genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology, 2014, 59, 109-120.	3.6	320
6	Spontaneous Control of Primary Hepatitis C Virus Infection and Immunity Against Persistent Reinfection. Gastroenterology, 2010, 138, 315-324.	0.6	316
7	A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction. Clinical Cancer Research, 2012, 18, 858-868.	3.2	304
8	Cellular immune selection with hepatitis C virus persistence in humans. Journal of Experimental Medicine, 2005, 201, 1741-1752.	4.2	278
9	Human Immunodeficiency Virus-Related Microbial Translocation and Progression of Hepatitis C. Gastroenterology, 2008, 135, 226-233.	0.6	251
10	Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology, 2014, 59, 2140-2151.	3.6	230
11	Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology, 2005, 42, 104-112.	3.6	211
12	Selection Pressure From Neutralizing Antibodies Drives Sequence Evolution During Acute Infection With Hepatitis C Virus. Gastroenterology, 2009, 136, 2377-2386.	0.6	207
13	TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer. Cancer Discovery, 2016, 6, 1366-1381.	7.7	196
14	Prospective Evaluation of Communityâ€Acquired Acuteâ€Phase Hepatitis C Virus Infection. Clinical Infectious Diseases, 2005, 40, 951-958.	2.9	195
15	Genome-Wide Association Study of Spontaneous Resolution of Hepatitis C Virus Infection: Data From Multiple Cohorts. Annals of Internal Medicine, 2013, 158, 235.	2.0	187
16	Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infectious Diseases, The, 2012, 12, 408-414.	4.6	186
17	Humoral Immune Response in Acute Hepatitis C Virus Infection. Clinical Infectious Diseases, 2005, 41, 667-675.	2.9	172
18	Approaches, Progress, and Challenges to Hepatitis C Vaccine Development. Gastroenterology, 2019, 156, 418-430.	0.6	162

#	Article	IF	CITATIONS
19	HIV and HCV Activate the Inflammasome in Monocytes and Macrophages via Endosomal Toll-Like Receptors without Induction of Type 1 Interferon. PLoS Pathogens, 2014, 10, e1004082.	2.1	159
20	Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. JCI Insight, 2017, 2, .	2.3	129
21	Direct identification of an endogenous peptide recognized by multiple HLA-A2.1-specific cytotoxic T cells Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 10275-10279.	3.3	122
22	Progress towards elimination goals for viral hepatitis. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 533-542.	8.2	118
23	The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV). Clinical Infectious Diseases, 2022, 74, 1268-1270.	2.9	118
24	High-Programmed Death-1 Levels on Hepatitis C Virus-Specific T Cells during Acute Infection Are Associated with Viral Persistence and Require Preservation of Cognate Antigen during Chronic Infection. Journal of Immunology, 2008, 181, 8215-8225.	0.4	114
25	Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection. New England Journal of Medicine, 2021, 384, 541-549.	13.9	101
26	Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. Hepatology, 2010, 52, 1581-1589.	3.6	100
27	Metabolic programs define dysfunctional immune responses in severe COVID-19 patients. Cell Reports, 2021, 34, 108863.	2.9	92
28	Global control of hepatitis C virus. Science, 2015, 349, 790-791.	6.0	90
29	Cell-free DNA maps COVID-19 tissue injury and risk of death and can cause tissue injury. JCI Insight, 2021, 6, .	2.3	86
30	Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection—the InC ³ Study. Journal of Infectious Diseases, 2015, 212, 1407-1419.	1.9	82
31	Monocytes Activate Natural Killer Cells via Inflammasome-Induced Interleukin 18 in Response to Hepatitis C Virus Replication. Gastroenterology, 2014, 147, 209-220.e3.	0.6	81
32	Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection. Cell Host and Microbe, 2018, 24, 717-730.e5.	5.1	78
33	Durable SARS-CoV-2 B cell immunity after mild or severe disease. Journal of Clinical Investigation, 2021, 131, .	3.9	76
34	A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients. American Journal of Transplantation, 2022, 22, 1253-1260.	2.6	73
35	Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses. Journal of Clinical Investigation, 2021, 131, .	3.9	72
36	Acceleration of Hepatitis C Virus Envelope Evolution in Humans Is Consistent with Progressive Humoral Immune Selection during the Transition from Acute to Chronic Infection. Journal of Virology, 2010, 84, 5067-5077.	1.5	70

#	Article	IF	CITATIONS
37	The More You Look, the More You Find: Effects of Hepatitis C Virus Testing Interval on Reinfection Incidence and Clearance and Implications for Future Vaccine Study Design. Journal of Infectious Diseases, 2012, 205, 1342-1350.	1.9	64
38	Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence. Immunologic Research, 2010, 47, 216-227.	1.3	63
39	Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology, 2012, 55, 1684-1691.	3.6	63
40	Hepatitis C Virus Immune Escape via Exploitation of a Hole in the T Cell Repertoire. Journal of Immunology, 2008, 181, 6435-6446.	0.4	61
41	Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration. Clinical Infectious Diseases, 2017, 64, 860-869.	2.9	61
42	The Clinical Course of COVID-19 in the Outpatient Setting: A Prospective Cohort Study. Open Forum Infectious Diseases, 2021, 8, ofab007.	0.4	55
43	Rare Birds in North America: Acute Hepatitis C Cohorts. Gastroenterology, 2009, 136, 26-31.	0.6	53
44	High Plasma Interleukin-18 Levels Mark the Acute Phase of Hepatitis C Virus Infection. Journal of Infectious Diseases, 2011, 204, 1730-1740.	1.9	51
45	A Fourth Dose of COVID-19 Vaccine Does Not Induce Neutralization of the Omicron Variant Among Solid Organ Transplant Recipients With Suboptimal Vaccine Response. Transplantation, 2022, 106, 1440-1444.	0.5	49
46	Cohort Profile: The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study. International Journal of Epidemiology, 2013, 42, 1649-1659.	0.9	48
47	Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The InC3 Study. PLoS ONE, 2015, 10, e0122232.	1.1	41
48	Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine?. Trends in Microbiology, 2018, 26, 854-864.	3.5	39
49	Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2. Journal of Virology, 2019, 93, .	1.5	37
50	CD4+T Cell–Dependent Reduction in Hepatitis C Virus–Specific Humoral Immune Responses after HIV Infection. Journal of Infectious Diseases, 2007, 195, 857-863.	1.9	33
51	Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance. Journal of Clinical Investigation, 2019, 129, 4786-4796.	3.9	33
52	Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. Gastroenterology, 2019, 156, 1496-1507.e7.	0.6	32
53	Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus. Journal of Viral Hepatitis, 2008, 15, 219-228.	1.0	31
54	Hepatitis C Virus Vaccines Among People Who Inject Drugs. Clinical Infectious Diseases, 2013, 57, S46-S50.	2.9	31

#	Article	IF	CITATIONS
55	The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design. Gut, 2016, 65, 112-123.	6.1	30
56	Challenges and Promise of a Hepatitis C Virus Vaccine. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036947.	2.9	30
57	Distinct Cytokine and Chemokine Dysregulation in Hospitalized Children With Acute Coronavirus Disease 2019 and Multisystem Inflammatory Syndrome With Similar Levels of Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 Shedding. Journal of Infectious Diseases, 2021, 224, 606-615.	1.9	30
58	Frequent Longitudinal Sampling of Hepatitis C Virus Infection in Injection Drug Users Reveals Intermittently Detectable Viremia and Reinfection. Clinical Infectious Diseases, 2013, 56, 405-413.	2.9	29
59	Immunogenicity and Cross-Reactivity of a Representative Ancestral Sequence in Hepatitis C Virus Infection. Journal of Immunology, 2012, 188, 5177-5188.	0.4	28
60	Differential Cytokine Signatures of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Influenza Infection Highlight Key Differences in Pathobiology. Clinical Infectious Diseases, 2022, 74, 254-262.	2.9	28
61	Factors Associated With the Control of Viral Replication and Virologic Breakthrough in a Recently Infected HIV-1 Controller. EBioMedicine, 2017, 16, 141-149.	2.7	27
62	Herpes simplex virus type 1 inflammasome activation in proinflammatory human macrophages is dependent on NLRP3, ASC, and caspase-1. PLoS ONE, 2020, 15, e0229570.	1.1	27
63	Immunity and Hepatitis C: A Review. Current HIV/AIDS Reports, 2013, 10, 51-58.	1.1	25
64	IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function. JCI Insight, 2022, 7, .	2.3	23
65	The NIH Lipo-COVID Study: A Pilot NMR Investigation of Lipoprotein Subfractions and Other Metabolites in Patients with Severe COVID-19. Biomedicines, 2021, 9, 1090.	1.4	22
66	Controlled Human Infection Model — Fast Track to HCV Vaccine?. New England Journal of Medicine, 2021, 385, 1235-1240.	13.9	22
67	Computational Reconstruction of Bole1a, a Representative Synthetic Hepatitis C Virus Subtype 1a Genome. Journal of Virology, 2012, 86, 5915-5921.	1.5	21
68	The Effect of Female Sex on Hepatitis C Incidence Among People Who Inject Drugs: Results From the International Multicohort InC3 Collaborative. Clinical Infectious Diseases, 2018, 66, 20-28.	2.9	21
69	Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African–American elite controllers/suppressors. Aids, 2011, 25, 385-387.	1.0	20
70	Antiâ€inflammatory cytokines, proâ€fibrogenic chemokines and persistence of acute <scp>HCV</scp> infection. Journal of Viral Hepatitis, 2013, 20, 404-413.	1.0	20
71	Not-so-innocent bystanders. Nature, 2014, 505, 492-493.	13.7	19
72	Acute Hepatitis C Virus Infection Induces Consistent Changes in Circulating MicroRNAs That Are Associated with Nonlytic Hepatocyte Release. Journal of Virology, 2015, 89, 9454-9464.	1.5	19

#	Article	IF	CITATIONS
73	Continued Elevation of Interleukin-18 and Interferon-Î ³ After Initiation of Antiretroviral Therapy and Clinical Failure in a Diverse Multicountry Human Immunodeficiency Virus Cohort. Open Forum Infectious Diseases, 2016, 3, ofw118.	0.4	19
74	Systemic Elevation of Proinflammatory Interleukin 18 in HIV/HCV Coinfection versus HIV or HCV Monoinfection. Clinical Infectious Diseases, 2017, 64, ciw771.	2.9	17
75	HIV-antibody complexes enhance production of type I interferon by plasmacytoid dendritic cells. Journal of Clinical Investigation, 2017, 127, 4352-4364.	3.9	17
76	Evolution of CD8 ⁺ T Cell Responses after Acute PARV4 Infection. Journal of Virology, 2013, 87, 3087-3096.	1.5	16
77	Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia. Journal of Infectious Diseases, 2016, 214, 1383-1389.	1.9	16
78	Medical school research ranking is associated with gender inequality in MSTP application rates. BMC Medical Education, 2018, 18, 187.	1.0	15
79	Higher Proinflammatory Cytokines Are Associated With Increased Antibody Titer After a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients. Transplantation, 2022, 106, 835-841.	0.5	15
80	SARS-CoV-2–specific immune responses in boosted vaccine recipients with breakthrough infections during the Omicron variant surge. JCI Insight, 2022, 7, .	2.3	15
81	Favorable Socioeconomic Status and Recreational Polydrug Use Are Linked With Sexual Hepatitis C Virus Transmission Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men. Open Forum Infectious Diseases, 2016, 3, ofw137.	0.4	14
82	Phylogenetic analysis of fullâ€length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC ³ Study. Journal of Viral Hepatitis, 2017, 24, 43-52.	1.0	14
83	Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing. Infection, Genetics and Evolution, 2019, 71, 36-41.	1.0	14
84	Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC ³ study. Journal of Viral Hepatitis, 2015, 22, 708-717.	1.0	13
85	Delayed Rise of Oral Fluid Antibodies, Elevated BMI, and Absence of Early Fever Correlate With Longer Time to SARS-CoV-2 RNA Clearance in a Longitudinally Sampled Cohort of COVID-19 Outpatients. Open Forum Infectious Diseases, 2021, 8, ofab195.	0.4	13
86	Lessons from Nature: Understanding Immunity to HCV to Guide Vaccine Design. PLoS Pathogens, 2016, 12, e1005632.	2.1	13
87	Use of Hepatitis C Virus (HCV) Immunoglobulin G Antibody Avidity as a Biomarker to Estimate the Population-Level Incidence of HCV Infection. Journal of Infectious Diseases, 2016, 214, 344-352.	1.9	12
88	Complex patterns of Hepatitis-C virus longitudinal clustering in a high-risk population. Infection, Genetics and Evolution, 2018, 58, 77-82.	1.0	12
89	Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection. JCI Insight, 2022, 7, .	2.3	12
90	SARS-CoV-2 vaccination diversifies the CD4+ spike-reactive T cell repertoire in patients with prior SARS-CoV-2 infection. EBioMedicine, 2022, 80, 104048.	2.7	12

#	Article	IF	CITATIONS
91	Markers of endothelial cell activation are associated with the severity of pulmonary disease in COVID-19. PLoS ONE, 2022, 17, e0268296.	1.1	12
92	Analysis of resistanceâ€associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents. Journal of Viral Hepatitis, 2017, 24, 37-42.	1.0	11
93	High-value laboratory testing for hospitalized COVID-19 patients: a review. Future Virology, 2021, 16, 691-705.	0.9	11
94	The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males. Drug and Alcohol Dependence, 2016, 169, 156-162.	1.6	10
95	Admixture analysis of spontaneous hepatitis C virus clearance in individuals of African descent. Genes and Immunity, 2014, 15, 241-246.	2.2	9
96	Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC3 Study. Journal of Clinical Virology, 2014, 61, 430-434.	1.6	8
97	Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection. Infection, Genetics and Evolution, 2017, 49, 88-96.	1.0	8
98	Opioids, Hepatitis C Virus Infection, and the Missing Vaccine. American Journal of Public Health, 2018, 108, 156-157.	1.5	8
99	Balancing Research, Teaching, Clinical Care, and Family: Can Physician-Scientists Have it All?. Journal of Infectious Diseases, 2018, 218, S32-S35.	1.9	8
100	Plasma virome and the risk of blood-borne infection in persons with substance use disorder. Nature Communications, 2021, 12, 6909.	5.8	8
101	Interventional Radiation Oncology (IRO): Transition of a magnetic resonance simulator to a brachytherapy suite. Brachytherapy, 2018, 17, 587-596.	0.2	7
102	Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C Infection. Clinical Infectious Diseases, 2020, 70, 123-131.	2.9	7
103	Ethical and Practical Issues Associated With the Possibility of Using Controlled Human Infection Trials in Developing a Hepatitis C Virus Vaccine. Clinical Infectious Diseases, 2020, 71, 2986-2990.	2.9	7
104	Genetic basis for variation in plasma IL-18 levels in persons with chronic hepatitis C virus and human immunodeficiency virus-1 infections. Genes and Immunity, 2017, 18, 82-87.	2.2	6
105	Fine-mapping of genetic loci driving spontaneous clearance of hepatitis C virus infection. Scientific Reports, 2017, 7, 15843.	1.6	6
106	Trends in hepatitis C treatment initiation among HIV/hepatitis C virus-coinfected men engaged in primary care in a multisite community health centre in Maryland: a retrospective cohort study. BMJ Open, 2019, 9, e027411.	0.8	6
107	Genomic variability of withinâ€host hepatitis C variants in acute infection. Journal of Viral Hepatitis, 2019, 26, 476-484.	1.0	6
108	B cell overexpression of FCRL5 and PD-1 is associated with low antibody titers in HCV infection. PLoS Pathogens, 2022, 18, e1010179.	2.1	6

#	Article	IF	CITATIONS
109	Trans-ancestral fine-mapping of MHC reveals key amino acids associated with spontaneous clearance of hepatitis C in HLA-DQl²1. American Journal of Human Genetics, 2022, 109, 299-310.	2.6	6
110	A Multiancestry Sex-Stratified Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. Journal of Infectious Diseases, 2021, 223, 2090-2098.	1.9	5
111	Multi-ancestry fine mapping of interferon lambda and the outcome of acute hepatitis C virus infection. Genes and Immunity, 2020, 21, 348-359.	2.2	5
112	Differentiation of Individuals Previously Infected with and Vaccinated for SARS-CoV-2 in an Inner-City Emergency Department. Journal of Clinical Microbiology, 2022, 60, jcm0239021.	1.8	5
113	Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies. Open Forum Infectious Diseases, 2022, 9, .	0.4	5
114	Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potency. Journal of Clinical Investigation, 2022, 132, .	3.9	5
115	IFNL3 genotype is associated with differential induction of IFNL3 in primary human hepatocytes. Antiviral Therapy, 2015, 20, 805-814.	0.6	4
116	People with HIV-1 Demonstrate Type 1 Interferon Refractoriness Associated with Upregulated USP18. Journal of Virology, 2021, 95, .	1.5	4
117	Interleukinâ€18 and tumor necrosis factorâ€Î± are elevated in solid organ transplant recipients with possible cytomegalovirus endâ€organ disease. Transplant Infectious Disease, 2021, 23, e13682.	0.7	4
118	Continued Virus-Specific Antibody-Secreting Cell Production, Avidity Maturation and B Cell Evolution in Patients Hospitalized with COVID-19. Viral Immunology, 2022, 35, 259-272.	0.6	4
119	Antibody avidity-based approach to estimate population-level incidence of hepatitis C. Journal of Hepatology, 2020, 73, 294-302.	1.8	3
120	Making Sense of HIV Innate Sensing. Immunity, 2013, 39, 998-1000.	6.6	2
121	Inconsistent temporal patterns of genetic variation of HCV among high-risk subjects may impact inference of transmission networks. Infection, Genetics and Evolution, 2019, 71, 1-6.	1.0	2
122	Cross-reactive antibodies facilitate innate sensing of dengue and Zika viruses. JCI Insight, 2022, 7, .	2.3	2
123	Interferon Lambda 4 Genotype Is Associated With Jaundice and Elevated Aminotransferase Levels During Acute Hepatitis C Virus Infection: Findings From the InC3 Collaborative. Open Forum Infectious Diseases, 2016, 3, ofw024.	0.4	1
124	Evolving trends in the prevalence of hepatitis C virus antibody positivity among HIVâ€infected men in a communityâ€based primary care setting. Journal of Viral Hepatitis, 2020, 27, 1202-1213.	1.0	1
125	Prophylactic Vaccines for the Hepatitis C Virus. , 2016, , 325-346.		1
126	Sequence analysis of peptides presented to the immune system by class I and class II MHC molecules. The Protein Journal, 1992, 11, 377-378.	1.1	0